



**Job Title:** Research Associate / Associate Scientist, Antibody Discovery

**Job description:**

The Antibody Discovery group at Verseau Therapeutics is looking for a highly motivated individual experienced in antibody and protein characterization. The successful candidate will play an important role in the discovery and development of novel biotherapeutics for immuno-oncology and inflammatory diseases, at an exciting, fast-paced start-up company. S/he will be responsible for screening and characterizing therapeutic antibodies using biophysical and cell biology techniques, as well as helping to build out the capabilities of the Antibody Discovery group, contributing to the development and implementation of assays and tools for antibody and protein characterization. S/he will also have the opportunity to work cross-functionally with Verseau scientists, as well as with external partners and CROs. S/he will be expected to participate in experimental design and planning, conduct experiments, maintain detailed records, and communicate results.

**Responsibilities will include (but are not limited to):**

- Designing and performing screening assays for therapeutic lead selection
- Characterizing target proteins and interactions
- Developing and implementing assays for antibody and protein characterization
- Working cross-functionally with Verseau scientists
- Recording and communicating findings in a timely manner

**Minimum requirements:**

- B.S./M.S. in Biochemistry or a related discipline with 2+ years of relevant research experience
- Experience with protein binding assays (e.g., ELISA, ForteBio Octet, Biacore)
- Experience with flow cytometry
- Experience with immunoassay development
- Experience with automation, a plus
- Excellent attention to detail, analytical, communication, and organizational skills, required



**About Verseau:**

Verseau Therapeutics is a multifaceted platform company with a broad focus on macrophages in human disease. The platform is built around a discovery engine combining computational approaches with original validation assays based on human samples. The Verseau pipeline will combine monoclonal antibodies, small molecules, and novel therapeutic modalities using nucleic-acid-carrying lipid nanoparticles. The company holds IP from MIT laboratories of Robert Langer and Daniel Anderson and has internal know-how around methods of delivery to macrophages. The early application of our platform is in cancer. The goal is to complement current approved therapies based on T cell checkpoint inhibitors and to broaden immune therapy utility by activating immune response to tumors with no prior T cell reactivity. Our goal is to build a leading biopharmaceutical brand with focus on macrophage-based therapies in a broad spectrum of disease indications.